Your browser doesn't support javascript.
loading
Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers.
Lin, Douglas I; Huang, Richard S P; Ladas, Ioannis; Keller, Rachel B; Patel, Nimesh R; Lakis, Sotirios; Decker, Brennan; Janovitz, Tyler; Mata, Douglas A; Ross, Jeffrey S; Vergilio, Jo-Anne; Elvin, Julia A; Herbst, Roy S; Mack, Philip C; Killian, Jonathan K.
Afiliación
  • Lin DI; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Huang RSP; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Ladas I; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Keller RB; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Patel NR; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Lakis S; Foundation Medicine GmbH, Pathology Department, Penzberg, Germany.
  • Decker B; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Janovitz T; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Mata DA; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Ross JS; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Vergilio JA; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Elvin JA; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
  • Herbst RS; Department of Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT, United States.
  • Mack PC; Division of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute at Mount Sinai, New York, NY, United States.
  • Killian JK; Department of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Front Oncol ; 14: 1328512, 2024.
Article en En | MEDLINE | ID: mdl-38444675
ABSTRACT

Background:

While many molecular assays can detect mutations at low tumor purity and variant allele frequencies, complex biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and genomic loss of heterozygosity (gLOH) require higher tumor purity for accurate measurement. Scalable, quality-controlled, tissue-conserving methods to increase tumor nuclei percentage (TN%) from tumor specimens are needed for complex biomarkers and hence necessary to maximize patient matching to approved therapies or clinical trial enrollment. We evaluated the clinical utility and performance of precision needle-punch enrichment (NPE) compared with traditional razor blade macroenrichment of tumor specimens on molecular testing success.

Methods:

Pathologist-directed NPE was performed manually on formalin-fixed, paraffin embedded (FFPE) blocks. Quality control of target capture region and quantity of residual tumor in each tissue block was determined via a post-enrichment histologic slide recut. Resultant tumor purity and biomarker status were determined by the computational analysis pipeline component of the FDA-approved next-generation sequencing (NGS) assay, FoundationOne®CDx. Following NPE implementation for real-world clinical samples, assay performance and biomarker (MSI, TMB, gLOH) detection were analyzed.

Results:

In real-world clinical samples, enrichment rate via NPE was increased to ~50% over a 2.5-year period, exceeding the prior use of razor blade macro-enrichment (<30% of cases) prior to NPE implementation due to proven efficacy in generating high quality molecular results from marginal samples and the ease of use for both pathologist and histotechnologists. NPE was associated with lower test failures, higher computational tumor purity, and higher rates of successful TMB, MSI and gLOH determination when stratified by pre-enriched (incipient) tumor nuclei percentage. In addition, challenging cases in which tumor content was initially insufficient for testing were salvaged for analysis of biomarker status, gene amplification/deletion, and confident mutant or wild-type gene status determination.

Conclusions:

Pathologist-directed precision enrichment from tissue blocks (aka NPE) increases tumor purity, and consequently, yields a greater number of successful tests and complex biomarker determinations. Moreover, this process is rapid, safe, inexpensive, scalable, and conserves patient surgical pathology material. NPE may constitute best practice with respect to enriching tumor cells from low-purity specimens for biomarker detection in molecular laboratories.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos